Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A

Arthritis & rheumatology (Hoboken, N.J.)28 Mar 2026Cited by 15 (Europe PMC)

PMID41903163PMCIDPMC13619038DOI10.1002/art.70134PepBankPUB-41903163

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, adding tirzepatide to ixekizumab raised the share reaching ACR50 plus at least 10% weight reduction at week 36 (31.7% versus 0.8%).
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab helped far more people reach joint and weight goals (31.7% versus 0.8%).
Peptide
Tirzepatide
Outcome
IncreaseACR50 with at least 10% weight reduction at week 36
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
US-approved doses · 36 weeksAs given in this study (human).
Measurements
responders
31.7%
ixekizumab + tirzepatide
responders
0.8%
ixekizumab alone
Source sentences
Summary
The primary end point was achieved with significant improvements in the IXE + TZP arm (31.7%) compared to IXE alone (0.8%) (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316301
02HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, adding tirzepatide to ixekizumab raised ACR50 response (33.5% versus 20.4%).
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab gave more people a joint improvement of 50% (33.5% versus 20.4%).
Peptide
Tirzepatide
Outcome
IncreaseACR50 response
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
US-approved dosesAs given in this study (human).
Measurements
ACR50
33.5%
ixekizumab + tirzepatide
ACR50
20.4%
ixekizumab alone
Source sentences
Summary
Greater improvements in ACR50 were demonstrated in IXE + TZP (33.5%) versus IXE alone (20.4%) (P = 0.02), with significant early separation at week 4 (nominal P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316302
03HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide separated early from ixekizumab alone on ACR50 at week 4.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab improved joint response as early as week 4.
Peptide
Tirzepatide
Outcome
IncreaseACR50 response at week 4
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
US-approved doses · 4 weeksAs given in this study (human).
Source sentences
Summary
with significant early separation at week 4 (nominal P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316303
04HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide nominally improved ACR20 versus ixekizumab alone.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab improved the joint response measure ACR20 compared with ixekizumab alone.
Peptide
Tirzepatide
Outcome
IncreaseACR20 response
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
US-approved dosesAs given in this study (human).
Source sentences
Summary
IXE + TZP demonstrated nominally significant improvements in ACR20 (P < 0.001), minimal disease activity (P < 0.05), and absolute Psoriasis Area and Severity Index score (P < 0.01) compared to IXE alone.
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316304
05HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide nominally improved minimal disease activity versus ixekizumab alone.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab improved minimal disease activity compared with ixekizumab alone.
Peptide
Tirzepatide
Outcome
IncreaseMinimal disease activity
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
US-approved dosesAs given in this study (human).
Source sentences
Summary
IXE + TZP demonstrated nominally significant improvements in ACR20 (P < 0.001), minimal disease activity (P < 0.05), and absolute Psoriasis Area and Severity Index score (P < 0.01) compared to IXE alone.
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316305
06HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide nominally improved the absolute PASI score versus ixekizumab alone.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab improved the psoriasis skin score compared with ixekizumab alone.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute PASI score
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Skin and hair · Skin and wound
Studied dose
US-approved dosesAs given in this study (human).
Source sentences
Summary
IXE + TZP demonstrated nominally significant improvements in ACR20 (P < 0.001), minimal disease activity (P < 0.05), and absolute Psoriasis Area and Severity Index score (P < 0.01) compared to IXE alone.
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316306
07HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide improved HAQ-DI by -0.2 versus ixekizumab alone.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab improved physical function scores compared with ixekizumab alone.
Peptide
Tirzepatide
Outcome
DecreaseHAQ-DI change
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
US-approved dosesAs given in this study (human).
Measurements
HAQ-DI difference
−0.2 points
ixekizumab + tirzepatide vs ixekizumab alone
Source sentences
Summary
IXE + TZP demonstrated significant improvements in PROs, including Health Assessment Questionnaire-Disability Index (∆ -0.2; nominal P < 0.001) and Functional Assessment of Chronic Illness Therapy-Fatigue (improvement of 3.8; nominal P < 0.01) compared to IXE alone.
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316307
08HumanRandomized controlled trialEfficacy outcome
In adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide improved FACIT-Fatigue by 3.8 versus ixekizumab alone.
In plain wordsIn adults with psoriatic arthritis and overweight, adding tirzepatide to ixekizumab reduced fatigue more than ixekizumab alone.
Peptide
Tirzepatide
Outcome
IncreaseFACIT-Fatigue improvement
Study
n = 271
Comparator
Ixekizumab alone
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Studied dose
US-approved dosesAs given in this study (human).
Measurements
FACIT-Fatigue difference
3.8 points
ixekizumab + tirzepatide vs ixekizumab alone
Source sentences
Summary
IXE + TZP demonstrated significant improvements in PROs, including Health Assessment Questionnaire-Disability Index (∆ -0.2; nominal P < 0.001) and Functional Assessment of Chronic Illness Therapy-Fatigue (improvement of 3.8; nominal P < 0.01) compared to IXE alone.
1 context sentence(design, population, supporting numbers)
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
Report a problemFND-4190316308

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

09HumanNot a test of Tirzepatide aloneRandomized controlled trialSafety outcome
In adults with active psoriatic arthritis and overweight or obesity, the safety profile of ixekizumab plus tirzepatide was consistent with previous studies of each drug.
In plain wordsIn adults with psoriatic arthritis and overweight, side effects of ixekizumab plus tirzepatide matched what earlier studies found for each drug.
Peptide
Tirzepatide
Outcome
Not applicableSafety profile
Study
n = 271
Outcome group
Adverse events · Whole body
Source sentences
Summary
Safety profiles were consistent with previous studies for each drug.
2 context sentences(design, population, supporting numbers)
Summary · context
with no new safety concerns.
Summary · context
TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4190316309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase not statedNCT07567378

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

JULIO GRANADOS MONTIELn = 30est. May 2026 to est. May 2029

Psoriatic Arthritis · Osteoarthitis · Knee · Diabetes (DM) · Type 2 Diabetes Mellitus (T2DM) · Obesity (Disorder) · Insulin Resistance Syndrome · Metabolic Syndrome · Heart Failure · Preserved Ejection Fraction · Coronary Artery Disease · Atrial Fibrillation (AF) · Non Alcholic Fatty Liver Disease · Sarcopenia · Pericardium

Trial page ClinicalTrials.govUpdated 12 May 2026

CompletedPhase 3NCT06588296

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Eli Lilly and Companyn = 27924 Sept 2024 to 23 Apr 2026

Psoriatic Arthritis · Obesity

Trial page ClinicalTrials.govUpdated 13 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.